Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
Metastatic and locally advanced breast cancer remain a fertile field for investigation of new chemotherapeutic agents and chemotherapy combinations. We administered combination chemotherapy with cyclophosphamide, doxorubicin, and gemcitabine to 20 women with metastatic and/or locally advanced breast cancer. The regimen was well tolerated, although it required granulocyte colony stimulating factor (G-CSF) support. This novel regimen resulted in a complete response rate of 20% and overall response rates of 89% (intent-to-treat response of 80%). Gemcitabine is a highly effective agent that warrants farther evaluation as a component of multidrug chemotherapy.
Levin
Mark
M
Lincoln Medical Center, 234 Maria de Hostos Blvd., Bronx, NY 10451, USA. mlevinmd@aol.com
Durgam
Sajani
S
Novetsky
Allan
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D003520:Cyclophosphamide; D000093542:Gemcitabine